IBEX (IBEX) Q3 2026: Health Tech Grows 54% as AI Partnership Lifts Margin Trajectory
IBEX’s Q3 results underscore its transition from legacy BPO to a tech-enabled, verticalized CX leader, with health tech and digital services now driving both growth and margin mix. The new Sierra AI partnership marks a strategic inflection, positioning IBEX to capture incremental high-margin revenue streams even as AI disrupts traditional call center volumes. Upgraded guidance signals management conviction in sustainable, repeatable expansion into FY27 and beyond.
Summary
- AI Integration Upside: Sierra partnership accelerates IBEX’s transition to higher-margin, tech-driven CX delivery.
- Health Tech Outperformance: Vertical growth now anchors U.S. profitability, replacing legacy telco drag.
- Guidance Raised: Upward revision reflects confidence in sustained margin and revenue expansion.
Business Overview
IBEX is a business process outsourcing (BPO) company specializing in customer experience (CX) solutions, integrating digital, omnichannel, and AI-driven services for large global clients. The company generates revenue by providing outsourced customer support, digital acquisition, and tech-enabled CX services, with major verticals including health tech, technology, retail and e-commerce, fintech, and travel/logistics. IBEX operates across onshore, nearshore, and offshore geographies, with a growing focus on high-margin digital and AI-powered offerings.
Performance Analysis
IBEX delivered record revenue growth of 17% in Q3, marking its fifth consecutive quarter of double-digit top-line expansion. Performance was anchored by exceptional 54% growth in health tech, which now comprises over 20% of total revenue, and 43% growth in the technology vertical. The retail and e-commerce and travel/logistics verticals also contributed, although at a more moderate pace, while telecom exposure continued to decline as legacy volumes rolled off.
Margin dynamics were shaped by mix shift and operational leverage. High-margin digital and omnichannel services rose to 82% of revenue, and onshore delivery grew sharply, driven by profitable health tech wins. SG&A leverage supported bottom-line growth, offsetting temporary margin headwinds from nearshore-to-offshore client transitions and a modest severance charge. Free cash flow doubled year-over-year, and the company maintained a net cash position while executing share repurchases.
- Vertical Mix Shift: Health tech and technology are now the primary revenue and margin engines, diluting legacy telco exposure.
- Digital Penetration: Digital and omnichannel services’ share of revenue reached a new high, reinforcing structural margin improvement.
- Client Diversification: No single client exceeds 9% of revenue, and IBEX continues to convert new wins into top-20 accounts.
Results validate IBEX’s strategy of targeting verticals and services with higher structural profitability, while maintaining operational discipline and capital allocation flexibility.
Executive Commentary
"Our strong results were again anchored by our two key pillars of growth, driving new wins with key logos and market share gains with existing clients, driven by our continued ability to outperform the competition operationally."
Bob Deccan, Chief Executive Officer
"We have structurally built IBEX so that our growth vectors are our highest margin regions, services, and vertical markets, and we expect that we will continue to be successful driving growth in these higher margin areas as new client wins, and growth in our embedded base continue to be focused in these areas."
Taylor, Chief Financial Officer
Strategic Positioning
1. AI-Driven CX Transformation
The Sierra partnership positions IBEX at the forefront of “BPO 3.0,” integrating generative AI with human expertise to deliver scalable CX solutions. Management expects these AI-powered services to be accretive to margin and to accelerate deal velocity, with early wins against both tech and BPO incumbents. The economic model is structured to capture software-like margins on AI volumes, supplementing traditional BPO revenue.
2. Health Tech and U.S. Market Reinvention
Health tech’s rapid expansion has transformed IBEX’s U.S. business from a margin laggard to a growth engine. The company’s ability to win large, sustainable contracts with leading healthcare payers and new entrants has replaced legacy telco drag, making U.S. onshore operations profitable and repeatable. Management emphasized that Q3 health tech gains are durable, not lumpy.
3. Margin Expansion Through Mix and Scale
IBEX’s structural shift toward higher-margin verticals and digital services is driving sustained margin expansion, even as it invests in capacity and absorbs temporary transition costs. The company’s flywheel—winning new clients, expanding share, and layering on AI solutions—reinforces both top-line and bottom-line growth vectors.
4. Disciplined Capital Allocation
Share repurchases, ongoing investment in high-demand regions, and a net cash balance reflect a balanced approach to growth and shareholder returns. Increased capex guidance signals confidence in demand and a commitment to supporting scalable, high-margin service delivery.
Key Considerations
IBEX’s Q3 demonstrates the compounding benefits of vertical focus, digital enablement, and proactive AI adoption. The company’s operational model is now built to capture both incremental revenue and margin as the industry shifts toward automation and complex, tech-enabled CX requirements.
Key Considerations:
- AI Revenue Accretion: Sierra partnership introduces a new, high-margin revenue stream, with early client wins validating the model and deal velocity.
- Vertical Diversification: Health tech and technology now anchor growth, reducing exposure to cyclical or commoditized segments.
- Operational Resilience: 100% client retention and 99.9% revenue retention highlight strong execution and sticky relationships.
- Capital Allocation Discipline: Share buybacks and targeted capex support both near-term returns and long-term capacity for growth.
Risks
AI adoption poses both opportunity and risk: If clients accelerate automation, traditional human-agent volumes could decline faster than IBEX can replace them with AI-powered services, especially if competitors close the technology gap. Client concentration remains a watchpoint despite progress, and any misstep in scaling new verticals or integrating AI solutions could impact both growth and margins. Macro volatility in client end-markets, especially retail or travel, could also influence demand.
Forward Outlook
For Q4, IBEX guided to:
- Revenue in the range of $638 to $642 million for FY26 (raised from $620 to $630 million)
- Adjusted EBITDA in the range of $82 to $84 million (raised from $80 to $82 million)
For full-year 2026, management raised guidance:
- Capex now expected at $25 to $30 million, up from $20 to $25 million, to meet higher demand in profitable regions
Management cited several drivers for the outlook:
- Ongoing strength in health tech and digital verticals
- Early pipeline momentum from the Sierra AI partnership
Takeaways
IBEX’s pivot to high-growth, high-margin verticals and rapid AI enablement is reshaping its business model, with the Sierra partnership set to further accelerate this transition.
- Margin Expansion Vector: AI-powered CX and digital services are structurally improving profitability, supporting upgraded guidance and long-term growth.
- Vertical Leadership: Health tech’s scale and sustainability now define the U.S. business, de-risking legacy telco exposure and smoothing seasonality.
- Future Watchpoint: Investors should monitor the pace of AI client adoption, competitive AI solutioning, and continued client diversification as IBEX scales its new business model.
Conclusion
IBEX’s Q3 marks a clear inflection toward a tech-enabled, diversified, and margin-accretive CX leader, with AI and health tech as central growth levers. The company’s ability to win, scale, and retain clients in demanding verticals, while integrating next-gen AI, positions it well for durable outperformance into FY27.
Industry Read-Through
IBEX’s results and management commentary signal a broader industry pivot from legacy, labor-arbitrage BPO (BPO 1.0) to “BPO 3.0,” where AI and vertical expertise define competitiveness. The Sierra partnership highlights the urgency for BPOs to integrate best-in-class AI rather than build in-house, as speed, deployment, and client outcomes become key differentiators. Health tech’s rapid growth suggests that verticalization and regulatory complexity create defensible moats, while legacy telco and commoditized segments face continued decline. Competitors lacking AI strategy or vertical depth risk share loss, and the bar for exceptional human-agent support is rising alongside automation. Investors should expect continued consolidation and margin bifurcation across the CX outsourcing sector.